News
-
Accelrys HEOS Goes Live On BT Cloud Environment
4/9/2013
Accelrys, Inc., a leading provider of scientific innovation lifecycle management software, recently announced that the cloud-based Accelrys HEOS information management and collaboration workspace is now live on BT for Life Sciences R&D cloud platform.
-
NeuroDerm Announces Positive Results Of A Phase I Study Of ND0612 For The Treatment Of Parkinson's Disease
3/4/2013
NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously sub-cutaneously through a patch pump. It is designed to provide steady levodopa blood levels for the reduction of motor complications in Parkinson's disease. Results of this study support the continued development of ND0612 for the treatment of Parkinson's disease.
-
Sanofi And Regeneron Report Positive Proof-of-Concept Data For Dupilumab
3/4/2013
PARIS and TARRYTOWN, N.Y., March 2, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.
-
Ability Pharmaceuticals Awarded A 1.2 Million Euros Grant To Develop Its Lipid Analog ABTL0812 For Lung And Pancreatic Cancer
2/6/2013
Ability Pharmaceuticals, a privately held biopharmaceutical company, announced recently that it was awarded a 36 month 1.2 Million Euros grant under the INNPACTO-2012 Collaborative Program from the Ministry of Economy and Competitiveness of the Government of Spain.
-
Xceleron And Crystal Pharmatech Announce Partnership To Improve Early Clinical Development Utilizing Absolute Bioavailability Trials And Solid-State Solutions
1/22/2013
Xceleron, a U.S.-based leader in the application of ultra-sensitive analytical technology to novel clinical designs, has announced a partnership that will offer drug developers early bioavailability data that will lead to optimized solid-state forms and formulations. The partnership with Crystal Pharmatech, a China-based, technology-driven, solid-state research CRO, will enable sponsors to make faster decisions in the early stages of development.
-
Lorus Therapeutics Announces Successful Dose Escalation Of Its Phase I Clinical Trial Of LOR-253 And Initiation Of A Biomarker Clinical Study In Cancer Patients
1/7/2013
Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer, today announced that its Phase I clinical study of LOR-253 has successfully escalated to the target dose level based on predicted and observed clinical effects without limitation by toxicity.
-
Theravance Announces Initiation Of Phase 2b Study With Its LAMA Candidate, TD-4208, For The Treatment Of COPD
12/11/2012
Theravance, Inc. (NASDAQ: THRX) announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD.
-
Dr. Brad Vince Of Vince & Associates Clinical Research Announces Award Of Nearly $10M Contract From The National Institute On Drug Abuse
9/19/2012
Vince & Associates Clinical Research announced it has been awarded a contract with the National Institute on Drug Abuse, part of the National Institutes of Health (NIH), to carry out clinical pharmacology studies to determine the pharmacokinetics and pharmacodynamics of new medication in humans.
-
ImmusanT Initiates Clinical Trials Of Nexvax2 Therapeutic Vaccine For Celiac Disease
9/4/2012
ImmusanT announced recently that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease.
-
Investigational Cis-urocanic Acid Eye Drops For Dry Eye Syndrome Well Tolerated, In Phase 1 Clinical Study
6/28/2012
Laurantis Pharma today announced that it has completed a phase 1 clinical study with its Cis-urocanic acid eye drops. The objective of the study was to investigate the tolerability and safety of the ophthalmic product as well as pharmacokinetics after single and repeated dosing.